Gilgamesh Pharmaceuticals

Last updated
Gilgamesh Pharmaceuticals
Industry Pharmaceutical; Psychedelic medicine
Founded2019;6 years ago (2019) [1]
Website www.gilgameshpharmaceutical.com

Gilgamesh Pharmaceuticals is a pharmaceutical company that is developing psychedelic and related drugs as medicines. [2] [3] [4] It is a "discovery stage" company and is focused on developing new chemical entities. [1]

Contents

Its drug candidates include the ketamine-related NMDA receptor antagonist blixeprodil (GM-1020; (R)-4-fluorodeschloroketamine or (R)-4-FDCK), the dimethyltryptamine (DMT)-related serotonergic psychedelic bretisilocin (GM-2505; 5-fluoro-N-methyl-N-ethyltryptamine or 5F-MET), the noribogaine-related κ-opioid receptor agonist GM-3009, and the non-hallucinogenic psychoplastogen GM-5022. [2] [3] [5] [6] [4] Another potential candidate is GM-2040, a putatively non-hallucinogenic serotonin 5-HT2A receptor agonist. [7]

The company was co-founded by Jonathan Sporn, Jeff Witkin, Dalibor Sames, Andrew Kruegel, and Mike Cunningham. [1] Cunningham is a research scientist at Gilgamesh. [8] Sames, Kruegel, and Cunningham have worked together at Sames's lab at Columbia University. [1]

In May 2024, AbbVie made an optional deal with Gilgamesh Pharmaceuticals to pay $65 million upright for rights to novel non-hallucinogenic psychoplastogens. [1] [9] [10] It also agreed to pay up to $1.95 billion for a series of psychoplastogens. [1] [9] [10]

See also

References

  1. 1 2 3 4 5 6 "Gilgamesh Pharmaceuticals". Psychedelic Science Review. Retrieved 20 February 2025.
  2. 1 2 Gunther, Marc (31 January 2023). "Gilgamesh Tweaks Known Psychedelics To Improve Therapies". Lucid News - Psychedelics, Consciousness Technology, and the Future of Wellness. Retrieved 20 February 2025.
  3. 1 2 Taylor, Phil (15 May 2024). "AbbVie takes option on Gilgamesh CNS drugs in $2bn deal". pharmaphorum. Retrieved 20 February 2025. The startup's in-house projects include GM-1020, a small-molecule NMDA receptor channel blocker – the mechanism of action for ketamine – which is in phase 2a clinical development for major depressive disorder (MDD). GM-1020 could provide an oral alternative to Johnson & Johnson's intranasally-administered ketamine-based therapy Spravato (esketamine), which has been approved by the FDA for treatment-resistant depression and MDD with suicidal ideation or behaviour. Also in Gilgamesh's pipeline are GM-2505, a short-acting serotonin 5-HT2A agonist in phase 2 for MDD, an oral neuroplastogen GM-5022 under evaluation for anxiety, depression, and other disorders, as well as GM-3009, an ibogaine analogue designed to have improved safety that Gilgamesh says has potential in PTSD, traumatic brain injury, and substance use disorders.
  4. 1 2 Baum, Stephanie (19 February 2025). "Delving into the Latest Updates on Gilgamesh Pharmaceuticals, Inc. with Synapse". Synapse. Retrieved 20 February 2025.
  5. ↑ Barton, Cheryl (18 June 2024). "Neuroplastogens: A novel approach to treat neurological diseases". pharmaphorum. Retrieved 20 February 2025.
  6. ↑ Shah, Arsalan (11 July 2024). "Exploring Psychedelics, Consciousness, and Altered States". The Psychedelic Pulse. Retrieved 20 February 2025.
  7. ↑ Hughes, Zoe; Klein, Adam; Dvorak, Dino; Austin, Eric; Kiss, Laszlo; Marek, Gerard; Sporn, Jonathan; Kruegel, Andrew (2023). "22. GM-2505 has Rapid Onset Antidepressant Activity and Causes Dose-Dependent Changes in qEEG With Increasing 5-HT2A Receptor Occupancy". Biological Psychiatry. 93 (9): S102 –S103. doi:10.1016/j.biopsych.2023.02.262.
  8. ↑ Jarow, Oshan (24 June 2023). "The largest psychedelic conference in history is surprisingly sane". Vox. Retrieved 20 February 2025.
  9. 1 2 Barrie, Robert (14 May 2024). "AbbVie makes a play for psychiatric treatments with $2bn Gilgamesh collaboration". Pharmaceutical Technology. Retrieved 20 February 2025.
  10. 1 2 Psychedelic Alpha (13 May 2024). "Breaking: AbbVie Inks Deal with Gilgamesh Pharmaceuticals". Psychedelic Alpha. Retrieved 20 February 2025.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.